China Glimepiride Market Report, 2013-2022 - Focus on the Third-Generation Sulfonylurea Insulin Secretagogue

DUBLIN, Dec. 4, 2018 /PRNewswire/ --

The "Investigation Report on China's Glimepiride Market, 2018-2022" report has been added to ResearchAndMarkets.com's offering.

Glimepiride is a third-generation sulfonylurea insulin secretagogue. Sanofi's brand-name drug (trade name: Amaryl) have been marketed in many countries after it was approved by the FDA (U.S. Food and Drug Administration) on Nov. 30, 1995.

Glimepiride is the sulfonylurea hypoglycemic agent that has best clinical effectiveness as well as the first sulfonylurea approved by the FDA to be used together with insulin. It does much better in sensitizing and simulating insulin than other sulfonylureas. For type 2 diabetic patients with insulin resistance (reduced glucose utilization in peripheral tissues), Glimepiride reduces blood glucose by sensitizing and simulating insulin. For type 2 diabetic patients with insulin secretion dysfunction, Glimepiride reduces blood glucose by stimulating insulin secretion.

According to the author, with the development of China's economy, the rise of urbanization level, and the aging of population, the life style of Chinese people is changing, which increases the obese population and the incidence of diabetes in China. It is estimated that the number of type 2 diabetic patients in China had surpassed 1 million by the end of 2017, and is growing by 1.5 million to 2 million every year. The growing number of diabetics in China promotes the growth of the antidiabetic drug market.

According to the author, generic products have sprung up one after another since 2004 when Sanofi (Beijing) Pharmaceutical Co., Ltd. launched Amaryl in China. In 2017, the market size of Glimepiride in China was about CNY 302 million. There are over 10 Glimepiride manufacturers in China. The major market players include Sanofi (Beijing) Pharmaceutical Co., Ltd., Jiangsu Wanbang Biopharmaceuticals Co., Ltd., CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd., and Yangtze River Pharmaceutical Group Guangzhou Hairui Pharmaceutical Co., Ltd. By sales value, in 2017, Sanofi (Beijing) Pharmaceutical Co., Ltd.'s Amaryl captured more than 80% share of China's Glimepiride market.

It is expected that as the number of diabetics continues to grow, China's Glimepiride market will have huge growth potential in the next few years.

Key Topics Covered:

1. Relevant Concepts of Glimepiride
1.1 Indications for Glimepiride
1.2 Development of Glimepiride in China
1.3 Governmental Approval of Glimepiride in China

2. Sales of Glimepiride in China, 2013-2017
2.1 Sales Value of Glimepiride
2.1.1 Overall Sales Value
2.1.2 Sales Value by Region
2.2 Sales Volume of Glimepiride
2.2.1 Overall Sales Volume
2.2.2 Sales Volume by Region
2.3 Sales of Glimepiride by Dosage Form in China, 2013-2017
2.3.1 Tablets
2.3.2 Capsules
2.3.3 Pills

3. Analysis on Major Glimepiride Manufacturers in China, 2013-2017
3.1 Analysis on Market Share of Major Glimepiride Manufacturers
3.1.1 Market Share by Sales Value
3.1.2 Market Share by Sales Volume
3.2 Sanofi (Beijing) Pharmaceutical Co., Ltd.
3.2.1 Enterprise Profile
3.2.2 Sales of Sanofi (Beijing) Pharmaceutical Co., Ltd.'s Glimepiride in China
3.3 Jiangsu Wanbang Biopharmaceuticals Co., Ltd.
3.3.1 Enterprise Profile
3.3.2 Sales of Jiangsu Wanbang Biopharmaceuticals Co., Ltd.'s Glimepiride in China
3.4 CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
3.5 Yangtze River Pharmaceutical Group Guangzhou Hairui Pharmaceutical Co., Ltd.
3.6 Sanofi

4. Prices of Glimepiride in China, 2017-2018
4.1 Sanofi (Beijing) Pharmaceutical Co., Ltd. (Amaryl)
4.2 Jiangsu Wanbang Biopharmaceuticals Co., Ltd. (Wansuping)
4.3 CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. (Linmeixin)
4.4 Yangtze River Pharmaceutical Group Guangzhou Hairui Pharmaceutical Co., Ltd. (Yousu)
4.5 Sanofi (Amaryl)

5. Prospect of China's Glimepiride Market, 2018-2022
5.1 Forecast on Market Size
5.2 Forecast on Market Trend

For more information about this report visit https://www.researchandmarkets.com/research/hc49n4/china_glimepiride?w=5

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Laura Wood, Senior Manager
press@researchandmarkets.com  

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/china-glimepiride-market-report-2013-2022---focus-on-the-third-generation-sulfonylurea-insulin-secretagogue-300760001.html

SOURCE Research and Markets